Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Natera, Inc.. A complete text table follows the diagram.
The prenatal testing base supplies scale, while personalized cancer monitoring is becoming the faster-growing second engine of the molecular diagnostics platform.
Swipe to explore
The 754,700 women's-health, organ-health, and other node is the arithmetic difference between reported total and oncology tests. The 14,400 software-and-partner node is the difference between total processed tests and laboratory-accessioned tests; it is an operational residual, not a separately reported test category.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Oncology tests | 1 | 259 | Signatera-led cancer monitoring |
| Women's, organ and other tests | 1 | 755 | Led by Panorama and Horizon |
| Total genetic tests processed | 2 | 1.0M | More than one million in 90 days |
| Tests accessioned in Natera labs | 3 | 999 | Full molecular workflow |
| Software and partner processing | 3 | 14.4 | Constellation and external workflows |
| From | To | Value |
|---|---|---|
| Oncology tests | Total genetic tests processed | 259 |
| Women's, organ and other tests | Total genetic tests processed | 755 |
| Total genetic tests processed | Tests accessioned in Natera labs | 999 |
| Total genetic tests processed | Software and partner processing | 14.4 |